ArticleJournal for immunotherapy of cancer2025

Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies.

Jay Jacoby et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.